Project description
Volatile biomarkers for schizophrenia management
Schizophrenia affects approximately 1 % of the global population, with a misdiagnosis rate ranging from 23 % to 40 %. The EU-funded VOLABIOS project aims to enhance schizophrenia management via the detection of volatile organic compounds (VOCs) in breath, urine, blood and skin as non-invasive biomarkers for early diagnosis. The project will conduct clinical studies involving subjects across six centres and a blind validation study with at-risk individuals. By combining VOC analysis with genomics, proteomics and transcriptomics and supported by a biobank of 4 000 samples and a dataset of 9 million records, the project seeks to uncover factors contributing to schizophrenia and improve diagnostic accuracy. Ultimately, VOLABIOS aims to pave the way for earlier diagnoses and better patient care.
Objective
Schizophrenia (SZ) impacts around 1% of the global population, posing diagnostic challenges that lead to a misdiagnosis rate of 23-40%. The need for reliable biomarkers is crucial to improve early detection and treatment outcomes. VOLABIOS aims to revolutionize SZ management by harnessing innovative real-time and portable spectrograph technology to validate volatile organic compounds (VOCs) as non-invasive and cost-effective biomarkers detectable during the early stages of the disease. This entails extensive data analysis, prospective clinical studies involving 3,692 subjects across six centres, and a blind validation study with 1,000 subjects, focusing on longitudinal monitoring of at-risk individuals to identify early SZ transition. To further substantiate the efficacy of VOCs and gain profound insights, VOLABIOS will integrate VOC analysis with genomics, proteomics, and transcriptomics. This integration will be supported by a biobank comprising approximately 4,000 samples and a dataset consisting of 9 million records. By considering external and personal risk factors as well as biological responses, VOLABIOS aims to unravel intricate correlations that contribute to SZ development. This comprehensive approach will enhance prediction accuracy, facilitate early detection, and improve management strategies. Furthermore, VOLABIOS plans to explore the real-time effects of validated VOCs through controlled in-vivo experiments using animal models, providing valuable information about associated cellular and molecular pathways. VOLABIOS's endeavours to validate and establish EU-wide SZ diagnosis protocols are set to significantly enhance patient care and healthcare efficiency, marking a substantial step forward in addressing the complexities surrounding SZ.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesgenetics
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomics
- medical and health sciencesclinical medicinepsychiatryschizophrenia
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
32000 Haifa
Israel
See on map
Participants (19)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
32000 Haifa
See on map
118 54 Athina
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
41071 SEVILLA
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
41013 Sevilla
See on map
52074 Aachen
See on map
44307 Kaunas
See on map
68330 Huningue
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3004-531 Coimbra
See on map
40225 Dusseldorf
See on map
3570802 HAIFA
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
57001 Thermi Thessaloniki
See on map
3001 Leuven
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
. ATHINA
See on map
26006 La Rioja
See on map
1000 Bruxelles / Brussel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
52074 Aachen
See on map
546 24 Thessaloniki
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
CB2 1TN Cambridge
See on map
1150 Wien
See on map